Literature DB >> 2804929

Klebsiella bacteremia. A 10-year review in a cancer institution.

G P Bodey1, L S Elting, S Rodriquez, M Hernandez.   

Abstract

A total of 368 episodes of Klebsiella bacteremia occurred in 330 cancer patients, representing a rate of four episodes per 1000 hospital admissions. Eighty-eight percent of these infections were acquired nosocomically and 58% of the patients received antibiotics during the preceding 10-day period. There was pulmonary infection in 24% of the patients, shock in 25%, and disseminated intravascular coagulation in 7%. The overall response rate was 69%. Response rates were significantly lower among patients with shock (25% versus 83%), hemorrhage (29% versus 76%), and pneumonia (37% versus 79%). The combination of a cephalosporin plus an aminoglycoside produced the highest response rate (79%). Klebsiella sp continue to be an important cause of infection in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804929     DOI: 10.1002/1097-0142(19891201)64:11<2368::aid-cncr2820641129>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae.

Authors:  S Albertí; D Alvarez; S Merino; M T Casado; F Vivanco; J M Tomás; V J Benedí
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 2.  Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients.

Authors:  C P Escalante; E B Rubenstein; K V Rolston
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

3.  C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins.

Authors:  S Albertí; G Marqués; S Camprubí; S Merino; J M Tomás; F Vivanco; V J Benedí
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

4.  Enterobacteriaceae bacteremias among cancer patients: an observational cohort study.

Authors:  Andrés F Henao-Martínez; Guido R González-Fontal; José R Castillo-Mancilla; Ivana V Yang
Journal:  Int J Infect Dis       Date:  2013-01-10       Impact factor: 3.623

5.  Review of Citrobacter bacteremia in cancer patients over a sixteen-year period.

Authors:  G Samonis; E Anaissie; L Elting; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

6.  Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy.

Authors:  J A Korvick; C S Bryan; B Farber; T R Beam; L Schenfeld; R R Muder; D Weinbaum; R Lumish; D N Gerding; M M Wagener
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

7.  A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides.

Authors:  M Trautmann; K Vogt; C Hammack; A S Cross
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

8.  A porin from Klebsiella pneumoniae: sequence homology, three-dimensional model, and complement binding.

Authors:  S Albertí; F Rodríquez-Quiñones; T Schirmer; G Rummel; J M Tomás; J P Rosenbusch; V J Benedí
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

9.  From the wound to the bench: exoproteome interplay between wound-colonizing Staphylococcus aureus strains and co-existing bacteria.

Authors:  Andrea N García-Pérez; Anne de Jong; Sabryna Junker; Dörte Becher; Monika A Chlebowicz; José C Duipmans; Marcel F Jonkman; Jan Maarten van Dijl
Journal:  Virulence       Date:  2018-01-01       Impact factor: 5.882

10.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.

Authors:  Michael Maes; Aristo Vojdani; Sunee Sirivichayakul; Decio S Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.